Showing results (91-100 of 101) with videos related to
Sort By:
Pageof 11
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 17, 2014
Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levelsMaria Mercedes Santoro, Lavinia Fabeni, Daniele Armenia, et al.The Journal of Antimicrobial Chemotherapy|July 19, 2024
HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21Lavinia Fabeni, Daniele Armenia, Isabella Abbate, et al.Retrovirology|June 26, 2014
The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort studyStefania Bellino, Antonella Tripiciano, Orietta Picconi, et al.Antiviral Therapy|April 13, 2019
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimenDaniele Armenia, Domenico Di Carlo, Alessandro Cozzi-Lepri, et al.Antiviral Therapy|January 25, 2013
Impact of pre-therapy viral load on virological response to modern first-line HAARTMaria Mercedes Santoro, Daniele Armenia, Claudia Alteri, et al.Vaccine|November 3, 2009
The preventive phase I trial with the HIV-1 Tat-based vaccineBarbara Ensoli, Valeria Fiorelli, Fabrizio Ensoli, et al.Plos One|December 24, 2019
Naïve/Effector CD4 T cell ratio as a useful predictive marker of immune reconstitution in late presenter HIV patients: A multicenter studyVeronica Bordoni, Bruno Brando, Pierluca Piselli, et al.Plos One|November 22, 2017
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trialBarbara Rossetti, Roberta Gagliardini, Genny Meini, et al.Journal of Global Antimicrobial Resistance|August 18, 2016
The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate+emtricitabine-containing HAART both in vivo and in vitroClaudia Alteri, Matteo Surdo, Velia Chiara Di Maio, et al.Vaccines|January 24, 2025
Reactogenicity and Immunogenicity Against MPXV of the Intradermal Administration of Modified Vaccinia Ankara Compared to the Standard Subcutaneous RouteValentina Mazzotta, Pierluca Piselli, Alessandro Cozzi Lepri, et al.Pageof 11